<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02420392</url>
  </required_header>
  <id_info>
    <org_study_id>H1407-176-598</org_study_id>
    <nct_id>NCT02420392</nct_id>
  </id_info>
  <brief_title>Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell</brief_title>
  <official_title>Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of dapagliflozin on the incretin sensitivity of the pancreatic beta
      cell.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of incretin sensitivity of pancreatic beta cell measured by hyperglycemic clamp with GLP-1 and GIP infusion</measure>
    <time_frame>From 60 minutes to 120 minutes during GLP-1 infusion under hyperglycemic clamp</time_frame>
    <description>Area under the curve of C-peptide level during GLP-1 infusion under hyperglycemic clamp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First phase insulin/C-peptide response</measure>
    <time_frame>From 0 to 10 minutes of hyperglycemic clamp</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second phase insulin/C-peptide response</measure>
    <time_frame>From 10 to 60 minutes of hyperglycemic clamp</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of insulin level during GLP-1 infusion under hyperglycemic clamp</measure>
    <time_frame>From 60 minutes to 120 minutes during GLP-1 infusion under hyperglycemic clamp</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of insulin/C-peptide level during GIP infusion under hyperglycemic clamp</measure>
    <time_frame>From 120 minutes to 180 minutes during GIP infusion under hyperglycemic clamp</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of incretin sensitivity between diabetes patients and normal glucose tolerance subjects</measure>
    <time_frame>From 60 minutes to 120 minutes during GLP-1 infusion under hyperglycemic clamp</time_frame>
    <description>Area under the curve of C-peptide level during GLP-1 infusion under hyperglycemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of first phase insulin/C-peptide response between diabetes patients and normal glucose tolerance subjects</measure>
    <time_frame>From 0 to 10 minutes of hyperglycemic clamp</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of second phase insulin/C-peptide response between diabetes patients and normal glucose tolerance subjects</measure>
    <time_frame>From 10 to 60 minutes of hyperglycemic clamp</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of area under the curve of insulin level during GLP-1 infusion under hyperglycemic clamp between diabetes patients and normal glucose tolerance subjects</measure>
    <time_frame>From 60 minutes to 120 minutes during GLP-1 infusion under hyperglycemic clamp</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of Area under the curve of insulin/C-peptide level during GIP infusion under hyperglycemic clamp between diabetes patients and normal glucose tolerance subjects</measure>
    <time_frame>From 120 minutes to 180 minutes during GIP infusion under hyperglycemic clamp</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test incretin sensitivity after dapagliflozin treatment in type 2 diabetes patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal glucose tolerance</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Test incretin sensitivity in subjects with normal glucose tolerance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea</description>
    <arm_group_label>Dapagliflozin treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes for dapagliflozin arm

          -  Normal glucose tolerance (fasting plasma glucose &lt;100 mgd/l, HbA1c &lt;6.0%) for normal
             glucose tolerance arm

          -  Age 18 to 75 years

          -  BMI &lt;35 kg/m2

          -  For type 2 diabetes patients, at least 3 months of treatment period and HbA1c 7.5 to
             11.0% and treatment with lifestyle modification and/or metformin or sulfonylurea

        Exclusion Criteria:

          -  Who is allergic to dapagliflozin

          -  Type 1 diabetes

          -  Patients with history of diabetic ketoacidosis

          -  Reduced renal function (eGFR &lt;60ml/min/1.73m2)

          -  Taking loop diuretics or dehydrated patient

          -  History of hypotension when taking hypertensive medication

          -  Diagnosed with heart failure

          -  Diagnosed with cerebral infarction

          -  Taking insulin, DPP-4 inhibitor, GLP-1 analogue, pioglitazone, alpha-glucosidase
             inhibitor

          -  Above upper limit of normal hematocrit range (male 39-52%, female 36-48%)

          -  Pregnant or breastfeeding women

          -  History of recurrent genitourinary infection

          -  AST/ALT more than two fold increased above normal upper limit

          -  Hemolytic disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Min Cho, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2015</study_first_submitted>
  <study_first_submitted_qc>April 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2015</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Young Min Cho</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

